A pharmacometric multistate model for predicting long-term treatment outcomes of patients with pulmonary TB
Journal of Antimicrobial Chemotherapy · 01.10.2024 · 79 (10) · 2561-2569
DOI: 10.1093/jac/dkae256 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 01.08.2024. Verfasst von Yu-Jou Lin und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Uppsala University, Uppsala, Sweden. Hauptthemen laut MEDLINE: Antitubercular Agents, Diarylquinolines, Tuberculosis, Pulmonary. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Uppsala University, Janssen Pharmaceuticals, NWO.
Abstract (Originalsprache)
Background
Studying long-term treatment outcomes of TB is time-consuming and impractical. Early and reliable biomarkers reflecting treatment response and capable of predicting long-term outcomes are urgently needed.
Objectives
To develop a pharmacometric multistate model to evaluate the link between potential predictors and long-term outcomes.
Methods
Data were obtained from two Phase II clinical trials (TMC207-C208 and TMC207-C209) with bedaquiline on top of a multidrug background regimen. Patients were typically followed throughout a 24 week investigational treatment period plus a 96 week follow-up period. A five-state multistate model (active TB, converted, recurrent TB, dropout, and death) was developed to describe observed transitions. Evaluated predictors included patient characteristics, baseline TB disease severity and on-treatment biomarkers.
Results
A fast bacterial clearance in the first 2 weeks and low TB bacterial burden at baseline increased probability to achieve conversion, whereas patients with XDR-TB were less likely to reach conversion. Higher estimated mycobacterial load at the end of 24 week treatment increased the probability of recurrence. At 120 weeks, the model predicted 55% (95% prediction interval, 50%–60%), 6.5% (4.2%–9.0%) and 7.5% (5.2%–10%) of patients in converted, recurrent TB and death states, respectively. Simulations predicted a substantial increase of recurrence after 24 weeks in patients with slow bacterial clearance regardless of baseline bacterial burden.
Conclusions
The developed multistate model successfully described TB treatment outcomes. The multistate modelling framework enables prediction of several outcomes simultaneously, and allows mechanistically sound investigation of novel promising predictors. This may help support future biomarker evaluation, clinical trial design and analysis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Uppsala University, Uppsala, Sweden.
- Department of Pharmacy, Radboud University Medical Center, Nijmegen, The Netherlands.
ORCID-Profile: Yu-Jou Lin
Förderung
- Uppsala University
- Janssen Pharmaceuticals
- NWO
Zitieren
APA
Lin, Y. J., Zou, Y., Karlsson, M. O., & Svensson, E. M. (2024). A pharmacometric multistate model for predicting long-term treatment outcomes of patients with pulmonary TB. Journal of Antimicrobial Chemotherapy, 79(10), 2561-2569. https://doi.org/10.1093/jac/dkae256
Vancouver
Lin YJ, Zou Y, Karlsson MO, Svensson EM. A pharmacometric multistate model for predicting long-term treatment outcomes of patients with pulmonary TB. Journal of Antimicrobial Chemotherapy. 2024;79(10):2561-2569. doi:10.1093/jac/dkae256
BibTeX
@article{Lin2024,
author = {Lin, Yu-Jou and Zou, Yuanxi and Karlsson, Mats O and Svensson, Elin M},
title = {A pharmacometric multistate model for predicting long-term treatment outcomes of patients with pulmonary TB},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2024},
volume = {79},
number = {10},
pages = {2561--2569},
doi = {10.1093/jac/dkae256}
}
EUVIMED